

B1 cont. CD11d/CD18 integrins or their ligands and which block the interaction of the CD11d/CD18 integrins or their ligands with vascular cells; molecules which inhibit expression of the CD11d/CD18 integrins or their ligands, and peptides and peptidomimetics derived from the CD11d/CD18 integrins or their ligands which block the interaction of the CD11d/CD18 integrins or their ligands with vascular cells or tissues, in an amount effective to inhibit or reduce stenosis or dependent restenosis of a blood vessel following injury to vascular tissue.

B2 503 D1
5. (amended) The method of claim 1 wherein the CD11d/CD18 integrin is selected from the group consisting of Mac-1, LFA-1, and p150,95[, and CD11d/CD18].

6. (amended) The method of claim 5 wherein the CD11d/CD18 integrin is Mac-1.

B3 503 D3
8. (amended) The method of claim 1 wherein the compound is selected from the group consisting of antibodies and antibody fragments that are immunoreactive with CD11d/CD18 integrins or their ligands and which block the interaction of the CD11d/CD18 integrins or their ligands with vascular cells[; molecules which inhibit expression of the CD11d/CD18 integrins or their ligands, and peptides and peptidomimetics derived from the CD11d/CD18 integrins or their ligands which block the interaction of the CD11d/CD18 integrins or their ligands with vascular cells or tissues].

9. (amended) The method of claim 5 wherein the CD11d/CD18 integrin is LFA-1 and the ligand is selected from the group consisting of ICAM-1, ICAM-2, ICAM-3.

Remarks

Rejections under 35 U.S.C. §112

Claims 1-6, 8, 11 and 12 were rejected under 35 U.S.C. §112 as non-enabled. This